Rosiglitazone inhibits early stage of glucolipotoxicity-induced beta-cell apoptosis

Hormone Research

Volumn 70, Issue 3, 2008, Pages 165-173

  Han, Seung Jin ^a   Kang, Eun Seok ^a,b   Hur, Kyu Yeon ^a   Kim, Hae Jin ^d   Kim, So Hun ^a   Yun, Chae Ok ^c   Choi, Sung E ^d   Ahn, Chul Woo ^a,b   Cha, Bong Soo ^a,b   Kang, Yup ^d   Lee, Hyun Chul ^a,b,e  

^a Department of Internal Medicine ^*

^b Yonsei University   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d Ajou University School of Medicine   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

Author keywords

Apoptosis; Diabetes mellitus; Glucolipotoxicity; Rosiglitazone

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; CASPASE 3; GLUCOSE; PALMITIC ACID; PLACEBO; ROSIGLITAZONE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL NUCLEUS; CELL PROTECTION; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG INHIBITION; ENZYME ACTIVITY; FATTY ACID BLOOD LEVEL; GLUCOLIPOTOXICITY; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; IN VIVO STUDY; INCUBATION TIME; INSULIN SENSITIVITY; MALE; METABOLIC PARAMETERS; NICK END LABELING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TREATMENT OUTCOME;

ANIMALS; APOPTOSIS; CASPASE 3; CELL LINE; CELL SURVIVAL; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DNA DAMAGE; FATTY ACIDS, NONESTERIFIED; GLUCOSE; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIC AGENTS; IMMUNOBLOTTING; IN SITU NICK-END LABELING; INSULIN; INSULIN-SECRETING CELLS; MALE; PALMITATES; RATS; RATS, INBRED OLETF; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 47949108186     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000137662     Document Type: Article

References (30)

1. Kahn SE: The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003;46:3-19.
2. Clark A, Wells CA, Buley ID, Cruickshank JK, Vanhegan RI, Matthews DR, Cooper GJ, Holman RR, Turner RC: Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res 1988;9:151-159.
3. Sakuraba H, Mizukami H, Yagihashi N, Wada R, Hanyu C, Yagihashi S: Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese type II diabetic patients. Diabetologia 2002;45:85-96.
4. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC: Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52:102-110.
5. Poitout V, Robertson RP: Minireview: secondary beta-cell failure in type 2 diabetes - a convergence of glucotoxicity and lipotoxicity. Endocrinology 2002;143:339-342.
6. El-Assaad W, Buteau J, Peyot ML, Nolan C, Roduit R, Hardy S, Joly E, Dbaibo G, Rosenberg L, Prentki M: Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. Endocrinology 2003;144:4154-4163.
7. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995;270:12953-12956.
8. Spiegelman BM: PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998;47:507-514.
9. Sreenan S, Sturis J, Pugh W, Burant CF, Polonsky KS: Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone. Am J Physiol 1996;271:E742-E747.
10. Higa M, Zhou YT, Ravazzola M, Baetens D, Orci L, Unger RH: Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. Proc Natl Acad Sci USA 1999;96:11513-11518.
11. Finegood DT, McArthur MD, Kojwang D, Thomas MJ, Topp BG, Leonard T, Buckingham RE: Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 2001;50:1021-1029.
12. Diani AR, Sawada G, Wyse B, Murray FT, Khan M: Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes. Am J Physiol Endocrinol Metab 2004;286:E116-E122.
13. Kawai T, Hirose H, Seto Y, Fujita H, Fujita H, Ukeda K, Saruta T: Troglitazone ameliorates lipotoxicity in the beta cell line INS-1 expressing PPAR gamma. Diabetes Res Clin Pract 2002;56:83-92.
14. Yang LY, Yang YN, Chen ZJ: The effect of peroxisome proliferator- activated receptor alpha and gamma ligands on free fatty acid-induced INS-1 cell impairment (in Chinese). Zhonghua Nei Ke Za Zhi 2003;42:847-850.
15. Cnop M, Hannaert JC, Pipeleers DG: Troglitazone does not protect rat pancreatic beta cells against free fatty acid-induced cytotoxicity. Biochem Pharmacol 2002;63:1281-1285.
16. Spector AA: Structure and lipid binding properties of serum albumin. Methods Enzymol 1986;128:320-339.
17. Severino C, Brizzi P, Solinas A, Secchi G, Maioli M, Tonolo G: Low-dose dexamethasone in the rat: a model to study insulin resistance. Am J Physiol Endocrinol Metab 2002;283:E367-E373.
18. Donath MY, Halban PA: Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications. Diabetologia 2004;47:581-589.
19. Paumen MB, Ishida Y, Muramatsu M, Yamamoto M, Honjo T: Inhibition of carnitine palmitoyltransferase I augments sphingolipid synthesis and palmitate-induced apoptosis. J Biol Chem 1997;272:3324-3329.
20. de Vries JE, Vork MM, Roemen TH, de Jong YF, Cleutjens JP, van der Vusse GJ, van Bilsen M: Saturated but not mono-unsaturated fatty acids induce apoptotic cell death in neonatal rat ventricular myocytes. J Lipid Res 1997;38:1384-1394.
21. Lupi R, Del Guerra S, Marselli L, Bugliani M, Boggi U, Mosca F, Marchetti P, Del Prato S: Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion. Am J Physiol Endocrinol Metab 2004;286:E560-E567.
22. Kawai T, Hirose H, Seto Y, Fujita H, Saruta T: Chronic effects of different fatty acids and leptin in INS-1 cells. Diabetes Res Clin Pract 2001;51:1-8.
23. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T: Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 1992;41:1422-1428.
24. Yoshikawa H, Kihara Y, Taguchi M, Yamaguchi T, Nakamura H, Otsuki M: Role of TGF-beta1 in the development of pancreatic fibrosis in Otsuka Long-Evans Tokushima Fatty rats. Am J Physiol Gastrointest Liver Physiol 2002;282:G549-G558.
25. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Enocksson S, Inzucchi SE, Shulman GI, Petersen KF: The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002;51:797-802.
26. Shimabukuro M, Zhou YT, Lee Y, Unger RH: Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem 1998;273:3547-3550.
27. Jia DM, Tabaru A, Nakamura H, Fukumitsu KI, Akiyama T, Otsuki M: Troglitazone prevents and reverses dyslipidemia, insulin secretory defects, and histologic abnormalities in a rat model of naturally occurring obese diabetes. Metabolism 2000;49:1167-1175.
28. Ovalle F, Bell DS: Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes. Diabetes Care 2004;27:2585-2589.
29. Choy JC, Granville DJ, Hunt DW, McManus BM: Endothelial cell apoptosis: biochemical characteristics and potential implications for atherosclerosis. J Mol Cell Cardiol 2001;33:1673-1690.
30. Jung TW, Lee JY, Shim WS, Kang ES, Kim SK, Ahn CW, Lee HC, Cha BS: Rosiglitazone protects human neuroblastoma SH-SY5Y cells against acetaldehyde-induced cytotoxicity. Biochem Biophys Res Commun 2006;340:221-227.